{"id":"W2571445838","doi":"10.1182/blood.v118.21.265.265","title":"Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Rituximab; Medicine; Internal medicine; Bortezomib; Oncology; Follicular lymphoma; Refractory (planetary science); Progression-free survival; Phases of clinical research; Biomarker; Population; Lymphoma; Clinical trial; Multiple myeloma; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001552496,0.0003352162,0.000763857,0.000311077,0.0002691117,0.0005430629,0.0002760047,0.0003776291,0.0009595997],"category_scores_gemma":[0.001142914,0.0001592608,0.0007022923,0.0003422496,0.0002122853,0.0002771364,0.0002538484,0.0005114641,0.0001728878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003811523,"about_ca_system_score_gemma":0.0003858883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000305774,"about_ca_topic_score_gemma":0.000621375,"domain_scores_codex":[0.9995913,0.0002260246,0.0000328424,0.00006894971,0.00003594306,0.00004488925],"domain_scores_gemma":[0.9994078,0.0001779835,0.0001753018,0.00005633008,0.00003881739,0.000143817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2849969,0.00340864,0.6193188,0.0003212169,0.002413451,0.0003028752,0.0002774479,0.001155218,0.0322692,0.0001070612,0.001625491,0.05380367],"study_design_scores_gemma":[0.02578016,0.05757545,0.903274,0.00004332897,0.001768469,0.0009200766,0.0002127015,0.00224185,0.005368246,0.0003207687,0.002452658,0.00004235675],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989839,0.0004730402,0.00008660716,0.00004191853,0.000005110669,0.00004985337,0.0002054051,0.000004874779,0.0001491761],"genre_scores_gemma":[0.9987693,0.0000942062,0.0002275282,0.00008197579,0.00001606752,0.00007553917,0.0006538863,0.000001861643,0.00007955435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001552496,"threshold_uncertainty_score":0.00821048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03461630046728208,"score_gpt":0.2997340328390153,"score_spread":0.2651177323717332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}